Catalyst Clinical Research Acquires Aptus Clinical to Accelerate European Expansion, Broaden Client Services, and Enhance Patient Impact

Today, Catalyst Clinical Research, a market-leading provider of clinical research services, announced a strategic acquisition of Aptus Clinical to expand the geographic reach of the two companies, and to enhance patient access to advanced, life-changing therapies. Together, the two entities will become one multi-region clinical research organization with an accelerated growth trajectory in both the...

Trial of wearable health technology for cancer patients opens

Trial of Wearable Health Technology for Cancer Patients Opens EMBRaCE - Enhanced Monitoring for Better Recovery and Cancer Experience A new trial opens in Greater Manchester today which is to test cutting-edge wearable technologies involving patients who have received cancer treatment. The commercially-available health sensors and devices produce a digital fingerprint of vital signs that...

Aptus Strengthens Commercial and Clinical Team

Aptus Clinical is delighted to strengthen and expand its commercial and clinical teams with four new employees. Within Clinical Services, Aptus has welcomed Ms. Noriega as CRA Manager, Mohamed Jama and Beauty Mutandari as  CTAs and promoted Kristin Cope to CTA manager. The commercial team has also introduced Amy Cheney, in a new role as Marketing...

Aptus Clinical announces the first patient has been dosed in the Artelo Biosciences’ CAReS Phase 1b/2a study in cancer anorexia

Aptus Clinical, as the full service CRO provider for the Phase 1b/2a Cancer Appetite Recovery Study (CAReS), has assisted Artelo Biosciences in the planning and running of this important study which investigates the potential for ART27.13 (a peripherally synthetic cannabinoid agonist), to alleviate anorexia associated with cancer, a condition with significant unmet need and no...

Aptus Clinical announces recruitment has started for COSMIC-19

Alderley Park-based Aptus Clinical Ltd today announced that recruitment has started on the innovative COSMIC-19 study, which they believe will help transform and shape clinical trial monitoring in the future. COSMIC-19 study (COntinuous Signs Monitoring in Covid-19 patients), sponsored by The Christie NHS Foundation Trust in collaboration with Manchester University Foundation NHS Trust, utilises advanced...

Aptus Clinical selected as clinical CRO by Artelo Biosciences

Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd.) to deliver the upcoming Phase 1B/2A trial of their synthetic cannabinoid, ART27.13. This latest agreement builds on an earlier research and development partnership agreement, where Aptus successfully designed and supported the critical...

Aptus Clinical enters into a global partnership agreement with Artelo Biosciences

LA JOLLA, CA – June 5, 2018 - Artelo Biosciences, Inc. (OTCQB: ARTL), a biopharmaceutical company focused on the development of therapeutic treatments that modulate the endocannabinoid system, today announced that it has entered into a global research and development partnership with Syngene International Ltd. (Syngene), an India-based integrated discovery-development service provider, through its wholly-owned...

Scroll to top
Cookie Consent with Real Cookie Banner